Key result
Pilsicainide significantly prolonged the effective refractory period of the distal pulmonary vein from 163 to 192 msec (P < 0.001) in patients with paroxysmal atrial fibrillation.
Why the study?
Does pilsicainide modify the electrophysiologic properties of pulmonary veins in patients with paroxysmal atrial fibrillation?
Population
28 patients with paroxysmal atrial fibrillation undergoing pulmonary vein mapping
Comparison
Pilsicainide infusion (1 mg/kg) vs Baseline (before infusion)
Design
Cohort
Authors
Loading...
Pilsicainide may modify pulmonary vein electrophysiology in paroxysmal AF; leaves open whether this supports pharmacologic isolation or improves outcomes.
Does pilsicainide modify the electrophysiologic properties of pulmonary veins in patients with paroxysmal atrial fibrillation?
Absolute Event Rate: 192% vs 163%
p-value: p=< 0.001
Pilsicainide modifies ERP heterogeneity and conduction properties in the pulmonary veins, suggesting it may terminate atrial fibrillation by pharmacologic pulmonary vein isolation.
Kumagai et al. (2004) studied Paroxysmal atrial fibrillation (n=28). Pilsicainide vs. Baseline (before infusion) was evaluated on Effective refractory period (ERP) of the distal pulmonary vein (p=< 0.001). Pilsicainide significantly prolonged the effective refractory period of the distal pulmonary vein from 163 to 192 msec (P < 0.001) in patients with paroxysmal atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: